Zavicefta (ceftazidime–avibactam) | Patogen dekning

Kun for helsepersonell

Søk

Logg inn

Logg ut

Legemiddel

Terapiområde

Utforsk mer

Materiell

Video/podkast

Nyhetsbrev

Kontakt oss

Om Zavicefta

Virkningsmekanisme

Patogen dekning

Tidlig hensiktsmessig behandling

IDSA anbefaling

Økonomiske holdepunkter

Spørsmål og svar om ZAVICEFTA

Pasientprofiler

HAP/VAP pasient

cUTI pasient

cIAI pasient

Pediatriske pasienter

Spørsmål og svar - FAQs

Effekt

Real-world evidence

Effektdata

Spørsmål og svar om effekt

Sikkerhet

Sikkerhet hos voksne

Sikkerhet hos barn/ungdom

Spørsmål og svar om sikkerhet

Dosering

Dosering hos voksne

Dosering hos barn/ungdom

Spørsmål og svar om dosering

Patogen dekning

ZAVICEFTA (ceftazidime–avibactam) has in vitro activity against CRE, including KPC- and OXA-48-producing strains,
MDR P. aeruginosa, and ESBL- and AmpC-producing bacteria^1–5

Including a spectrum of activity against Gram-negative pathogens versus other BL/BLI^4–16

Scroll left to view table

Download our spectrum of activity one-pager for more information on
ZAVICEFTA’s pathogen coverage in comparison to competitor treatments.

ZAVICEFTA’s broad-spectrum Gram-negative pathogen coverage can be used across a range of indications^1,4*

Scroll left to view table

HAP/VAP

Discover more about HAP/VAP in a clinical setting.

Infectious Thinking

Listen to our ‘Infectious Thinking’ podcast on Spotify, as top medical experts discuss the challenges of MDR infections in high-risk patients.

With superior and comparable susceptibility against Gram-negative pathogens vs. competitors^17†‡

ESBL/CRE

Enterobacterales/
P. aeruginosa

MDR P. aeruginosa/
XDR P. aeruginosa

Tab Number 4

Tab Number 5

Adapted from Sader HS, et al. 2020 and supplementary information¹⁷

ZAVICEFTA is effective against infections with Enterobacterales and P. aeruginosa with EUCAST minimum inhibitory concentrations as follows:^4§

Scroll left to view table

ZAVICEFTA is active against a broad range of Gram-negative resistance mechanisms, including class A (e.g. ESBL and KPC), class C (e.g. AmpC) and some class D^_¶ (including OXA-48) β-lactamases.⁴

Footnotes:

^*_{^{In vitro data indicate that the following species are not susceptible to ZAVICEFTA: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), anaerobes, Enterococcus spp., Stenotrophomonas maltophilia and Acinetobacter spp.}}
^†_{^{Isolates from patients hospitalised with pneumonia in US medical centres in 2017–2018 as per EUCAST criteria.}}¹⁷
^‡_{^{ZAVICEFTA’s (ceftazidime–avibactam) range of in vitro activity against β-lactamases does not necessarily predict clinical success.}}⁹
^§_{^{The breakpoint is the MIC that is the cut-off between susceptible and resistant isolates. If the MIC is less than or equal to the susceptibility breakpoint, the bacteria are considered susceptible.}}¹⁸
^¶_{^{Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many of the class D enzymes.}}

Abbreviations:

^{BL, β-lactam; BLI, β-lactamase inhibitor; CRE, carbapenem-resistant Enterobacterales; CTX-M, cefotaximase-Munich; ESBL, extended-spectrum β-lactamase; EUCAST, European Committee on Antimicrobial Susceptibility Testing; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; MDR, multidrug infections; OXA, oxacillinase; SHV, sulphydryl variable; TEM, Temoniera; VAP, ventilator-acquired pneumonia; XDR, extensively drug-resistant.}

References:

Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.

Mazuski JE, et al. Surg Infect 2017;18:1–76.

Pogue JM, et al. Clin Infect Dis 2019;68:519–24.

ZAVICEFTA Summary of Product Characteristics, 2022.

Zhanel GG, et al. Drugs 2013;73:159–77.

Lagacé-Wiens P, et al. Core Evidence 2014;9:13–25.

Bush K. Int J Antimicrob Agents 2015;46:483–93.

Wright H, et al. Clin Microbiol Infect 2017;23:704–12.

Munita J, et al. Clin Infect Dis 2017;65:158–61.

Zerbaxa. Summary of Product Characteristics, 2015.

Sader H, et al. Diagn Microbiol Infect Dis 2015;83:389–94.

Walkty A, et al. Antimicrob Agents Chemother 2011;55:2992–4.

Lomovskaya O, et al. Antimicrob Agents Chemother 2017;61:e01443-17.

Recarbrio. Summary of Product Characteristics, 2020.

Recarbrio. Prescribing Information, 2019.

Smith JR, et al. Pharmacotherapy 2020;40:343–56.

Sader HS, et al. Diagn Microbiol Infect Dis 2020;96:114833 and supplementary information.

The Open University. Antimicrobial susceptibility testing. Available at: https://www.open.edu/openlearncreate/mod/oucontent/view.php?id=172394&printable=1. (last accessed July 2022).

Preparatomtale

PP-ZVA-NOR-0141 Mai 2023

Om ZAVICEFTA

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00

PP-BCP-NOR-0001 juni 2023

Du forlater nå PfizerPro.no

Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.